Sagent Pharmaceuticals (SGNT) Tops Q3 EPS by 1c

Sagent Pharmaceuticals (NASDAQ: SGNT) reported Q3 EPS of ($0.05), $0.01 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $75.2 million versus the consensus estimate of $73.84 million.

Sagent Pharmaceuticals reaffirmed FY2015 guidance.

For earnings history and earnings-related data on Sagent Pharmaceuticals (SGNT) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• TJX stock drops as profit outlook falls short of analyst estimates
• Estee Lauder shares jump as fiscal 2027 profit forecast tops estimates